We are live on ! Find out more
NMRA icon

Neumora Therapeutics
NMRA

115 hedge funds and large institutions have $65.2M invested in Neumora Therapeutics in 2025 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 31 increasing their positions, 30 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more call options, than puts

Call options by funds: $282K | Put options by funds: $130K

3% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 30

9.45% less ownership

Funds ownership: 49.72% → 40.27% (-9.5%)

14% less funds holding

Funds holding: 134 → 115 (-19)

36% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 50

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

92% less capital invested

Capital invested by funds: $852M → $65.2M (-$786M)

Holders
115
Holders Change
-19
Holders Change %
-14.18%
% of All Funds
1.54%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.01%
New
32
Increased
31
Reduced
30
Closed
50
Calls
$282K
Puts
$130K
Net Calls
+$152K
Net Calls Change
-$2.42M

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$3.19M
2
TCM
Tang Capital Management
California
+$2.4M
3
Renaissance Technologies
Renaissance Technologies
New York
+$2.16M
4
GCM
Graham Capital Management
Connecticut
+$1.88M
5
Bank of America
Bank of America
North Carolina
+$1.32M

Top Sellers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
-$42.4M
2
Capital International Investors
Capital International Investors
California
-$39.2M
3
EC
EcoR1 Capital
California
-$22M
4
RSCM
Rock Springs Capital Management
Maryland
-$10.1M
5
O
OrbiMed
New York
-$8.53M
Name Holding Trade Value Shares
Change 		Change in
Stake
VEA
151
Virtus ETF Advisers
New York
– -$71.2K -6,720 Closed
QL
152
Quarry LP
New York
– -$53K -5,000 Closed
Royal Bank of Canada
153
Royal Bank of Canada
Ontario, Canada
– -$3.51K -2,051 -79%
RS
154
R Squared
Hong Kong
– -$12.8K -1,210 Closed
AWM
155
Avior Wealth Management
Nebraska
– -$12.6K -1,192 Closed
BIG
156
Brooklyn Investment Group
New York
– -$5.34K -504 Closed
VCM
157
Versant Capital Management
Arizona
– -$4.46K -421 Closed
Osaic Holdings
158
Osaic Holdings
Arizona
– -$2.18K -206 Closed
Comerica Bank
159
Comerica Bank
Texas
– -$1.35K -127 Closed
AAP
160
Arax Advisory Partners
Colorado
– -$965 -91 Closed
LC
161
Lindbrook Capital
California
– -$509 -48 Closed
AF
162
Allworth Financial
California
– -$67 -32 Closed
GI
163
GAMMA Investing
California
– -$170 -16 Closed
WCM
164
WealthTrak Capital Management
Virginia
– -$106 -10 Closed
C
165
Covestor
United Kingdom
– +$63 +37 +370%
CAL
166
Capital Advisors Ltd
Ohio
– +$87 +51 New
3 4 5 6
7

NMRA Hedge Fund Activity: Q1 2025 in Review

115 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q1 2025, worth a combined $65.2M — down 92% from $852M a quarter earlier.

Sellers outnumbered buyers: 50 funds closed out of NMRA and 32 opened new positions — a net loss of 18 holders — while 30 trimmed existing stakes and 31 added.

The largest buyer was UBS Group, adding an estimated $3.19M. The largest seller was Deep Track Capital, exiting entirely with an estimated $42.4M sold.

  • 115 institutional investors held Neumora Therapeutics (NMRA) as of Q1 2025, down from 134 in Q4 2024.
  • Funds reported $65.2M of Neumora Therapeutics stock for Q1 2025, down 92% quarter-over-quarter.
  • 32 funds opened new Neumora Therapeutics positions in Q1 2025 and 50 closed out, a net change of -18 holders.
  • The largest Neumora Therapeutics buyer in Q1 2025 was UBS Group, an estimated $3.19M added.
  • The largest Neumora Therapeutics seller in Q1 2025 was Deep Track Capital, an estimated $42.4M sold.

Based on aggregated 13F filings for Q1 2025.